The development of new treatments for castrate resistant prostate cancer (CRPC) must
address such challenges as intrinsic tumor heterogeneity and phenotypic plasticity. Combined …

Cancer genomic heterogeneity presents significant challenges for understanding oncogenic
processes and for cancer’s clinical management. Variation in driver mutation frequency …

Comparative studies of naturally occurring canine cancers have provided new insight into
many areas of cancer research. Development and validation of circulating tumor DNA (ctDNA) …

Background Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the
treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its …

Sorafenib is a multi-kinase small molecule inhibitor that targets serine/threonine and tyrosine
kinases including the RAF kinase family, VEGFR-2, and PDGFR. The aim of this study was …

9 Gene Editing and Gene Therapy in Oncology Page 1 9 Gene Editing and Gene Therapy
in Oncology WESLEY A. WIERSON 1*, ALEX M. ABEL 1, ELIZABETH L. SIEGLER 2 …

Comparative studies of naturally-occurring canine cancers have provided new insight into
many areas of cancer research. The inclusion of pet dogs in the development and validation …

Myelodysplastic syndrome (MDS) is a hematopoietic malignancy characterized by
peripheral cytopenias due to bone marrow (BM) failure. Megakarypoiesis, megakaryocyte (MK) …

Prostate cancer (PCa) demonstrates significant intra and inter tumor heterogeneity, similar
to many other solid tumors. The “gold standard” of therapy for metastatic prostate cancer is …

Androgen-deprivation therapy (ADT) remains the gold-standard therapy for prostate cancer (PrCa),
and although ADT is initially effective, most men progress to castrate-resistant …